Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.

Slides:

Advertisements

Similar presentations

5-Azacitidine For Myelodysplasia Before Allogeneic Hematopoietic Cell Transplantation Field T et al. Bone Marrow Transplant 2009:[Epub ahead of print].

Advertisements

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Who is the best donor for a related HLA haplotype-mismatched transplant? by Yu Wang, Ying-Jun Chang, Lan-Ping Xu, Kai-Yan Liu, Dai-Hong Liu, Xiao-Hui Zhang,

Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children Daihong.

Supplemental table 1 Patients' characteristics Variables Number

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors.

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

Gupta V, Tallman MS, Weisdorf DJ

Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study by Yu Wang, Qi-Fa Liu, Lan-Ping Xu, Kai-Yan Liu,

Long-term outcome after bone marrow transplantation for severe aplastic anemia by Lionel Ades, Jean-Yves Mary, Marie Robin, Christèle Ferry, Raphael Porcher,

Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning by Navneet S. Majhail, Ruta Brazauskas,

Solid cancers after allogeneic hematopoietic cell transplantation

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous.

Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients.

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

Does the Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study in a Large Cohort of Umbilical.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations Yachiyo.

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is.

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia: A Japanese National Registry Study

Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes Junya Kanda, Kazuhiro Ikegame,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia Mei-Jie.

Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow.

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions Darius Sairafi, Mats Remberger, Michael.

Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute.

Comparison of Cord Blood Transplantation with Unrelated Bone Marrow Transplantation in Patients Older than Fifty Years Masatsugu Tanaka, Koichi Miyamura,

Alternative Donor Transplantation for Older Patients with Acute Myeloid Leukemia in First Complete Remission: A Center for International Blood and Marrow.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Marrow Fibrosis as a Risk Factor for Posttransplantation Outcome in Patients with Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with Multilineage.

Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma George.

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation.

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

An Exploratory Analysis of Mitochondrial Haplotypes and Allogeneic Hematopoietic Cell Transplantation Outcomes Julie A. Ross, Jakub Tolar, Logan G. Spector,

Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High- Risk Acute Lymphoblastic Leukemia Samer A. Srour, Denái R. Milton,

Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant.

Impact of Donor and Recipient Sex and Parity on Outcomes of HLA-Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation Alison W. Loren,

Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide by Shannon R. McCurdy, Mei-Jie Zhang, Andrew.

Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older Vikas Gupta, Andrew Daly,

Haplo-Cord Transplantation Using CD34+ Cells from a Third-Party Donor to Speed Engraftment in High-Risk Patients with Hematologic Disorders Mi Kwon,

CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50.

Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? by Tara M. Robinson, Ephraim J. Fuchs,

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.

Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome Scott R. Solomon, Bipin N. Savani, Richard.

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents Moreno Festuccia, Kelsey Baker, Theodore.

Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and.

Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome.

Outcomes of patients who developed subsequent solid cancer after hematopoietic cell transplantation by Yoshihiro Inamoto, Tomohiro Matsuda, Ken Tabuchi,

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.

Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia

by David Deambrosis, Su Han Lum, Ryan M

Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells by Yi-Bin Chen, Jennifer Le-Rademacher,

PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL by Peter Dreger, Anna Sureda, Kwang.

Mismatched Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies Mary Eapen, Paul O'Donnell,

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Hematopoietic Cell Transplantation for Adult Patients With Myelodysplastic Syndromes and Myeloproliferative Disorders Martin Benesch, MD, H. Joachim.

Mary Eapen Biology of Blood and Marrow Transplantation

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone.

Presentation transcript:

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael Hemmer, Waleska S. Perez, Patricia Steinert, Mary M. Horowitz, and H. Joachim Deeg BloodAdv Volume 2(16):2095-2103 August 28, 2018 © 2018 by The American Society of Hematology

Mary Eapen et al. Blood Adv 2018;2:2095-2103 © 2018 by The American Society of Hematology

Grade 3-4 acute GVHD by conditioning regimen intensity. Grade 3-4 acute GVHD by conditioning regimen intensity. The 6-month incidence of grade 3-4 acute GVHD was 21% (95% CI, 17-24) for Bu4/Cy, 19% (95% CI, 16-23) for Flu/Bu4, 15% (95% CI, 11-19) for Flu/Bu4 + ATG, 16% (95% CI, 13-20) for Flu/Bu2, 14% (95% CI, 10-18) for Flu/Bu2 + ATG, 19% (95% CI, 14-25) for Flu/Mel, and 26% (95% CI, 16-37) for Flu/Mel + ATG. Mary Eapen et al. Blood Adv 2018;2:2095-2103 © 2018 by The American Society of Hematology

Chronic GVHD by conditioning regimen intensity. Chronic GVHD by conditioning regimen intensity. The 2-year incidence of chronic GVHD was 62% (95% CI, 58-66) for Bu4/Cy, 60% (95% CI, 55-64) for Flu/Bu4, 42% (95% CI, 36-48) for Flu/Bu4 + ATG, 52% (95% CI, 47-57) for Flu/Bu2, 44% (95% CI, 37-50) for Flu/Bu2 + ATG, 56% (95% CI, 49-63) for Flu/Mel, and 31% (95% CI, 20-43) for Flu/Mel + ATG. Mary Eapen et al. Blood Adv 2018;2:2095-2103 © 2018 by The American Society of Hematology

NRM and relapse by conditioning regimen intensity. NRM and relapse by conditioning regimen intensity. (A) The 3-year incidence of NRM adjusted for age, sex, performance score, HCT-CI, diagnosis, and donor type/donor-recipient HLA match was 27% (95% CI, 22-31) for Bu4/Cy, 27% (95% CI, 23-32) for Flu/Bu4, 23% (95% CI, 18-29) for Flu/Bu4 + ATG, 18% (95% CI, 14-22) for Flu/Bu2, 18% (95% CI, 18-24) for Flu/Bu2 + ATG, 27% (95% CI, 21-34) for Flu/Mel, and 27% (95% CI, 18-37) for Flu/Mel + ATG. (B) The 3-year incidence of relapse adjusted for performance score, HCT-CI, diagnosis, disease risk index, and donor type/donor-recipient HLA match was 32% (95% CI, 28- 36) for Bu4/Cy, 32% (95% CI, 27-36) for Flu/Bu4, 41% (95% CI, 34-47) for Flu/Bu4 + ATG, 46% (95% CI, 41-51) for Flu/Bu2, 56% (95% CI, 49-62) for Flu/Bu2 + ATG, 22% (95% CI, 16-28) for Flu/Mel, and 28% (95% CI, 17-41) for Flu/Mel + ATG. Mary Eapen et al. Blood Adv 2018;2:2095-2103 © 2018 by The American Society of Hematology

RFS and overall survival by conditioning regimen intensity. RFS and overall survival by conditioning regimen intensity. (A) The 3-year probability of RFS adjusted for age, performance score, HCT-CI, diagnosis, and disease risk index was 44% (95% CI, 39-48) for Bu4/Cy, 44% (95% CI, 39-48) for Flu/Bu4, 38% (95% CI, 32-44) for Flu/Bu4 + ATG, 38% (95% CI, 33-43) for Flu/Bu2, 31% (95% CI, 26-37) for Flu/Bu2 + ATG, 52% (95% CI, 45-59) for Flu/Mel, and 44% (95% CI, 33-55) for Flu/Mel + ATG. (B) The 3-year probability of survival adjusted for age, performance score, HCT-CI, and disease risk index was 51% (95% CI, 46-56) for Bu4/Cy, 48% (95% CI, 43-53) for Flu/Bu4, 42% (95% CI, 36-48) for Flu/Bu4 + ATG, 47% (95% CI, 42-52) for Flu/Bu2, 41% (95% CI, 35-47) for Flu/Bu2 + ATG, 57% (95% CI, 50-64) for Flu/Mel, and 46% (95% CI, 34-57) for Flu/Mel + ATG. Mary Eapen et al. Blood Adv 2018;2:2095-2103 © 2018 by The American Society of Hematology